Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HBIO 
Harvard Bioscience Inc (HBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: HBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 46.04% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.63M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 370959 | Beta 1.47 | 52 Weeks Range 0.35 - 4.45 | Updated Date 04/11/2025 |
52 Weeks Range 0.35 - 4.45 | Updated Date 04/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.18% | Operating Margin (TTM) 1.87% |
Management Effectiveness
Return on Assets (TTM) -2.23% | Return on Equity (TTM) -18.19% |
Valuation
Trailing PE - | Forward PE 14.93 | Enterprise Value 57390932 | Price to Sales(TTM) 0.19 |
Enterprise Value 57390932 | Price to Sales(TTM) 0.19 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA 179.26 | Shares Outstanding 44074500 | Shares Floating 28869663 |
Shares Outstanding 44074500 | Shares Floating 28869663 | ||
Percent Insiders 7.05 | Percent Institutions 82.28 |
Analyst Ratings
Rating 5 | Target Price 6.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Harvard Bioscience Inc
Company Overview
History and Background
Harvard Bioscience, Inc. was founded in 1901. Initially focused on educational models, it has evolved into a global developer, manufacturer, and marketer of a broad range of specialized products used to advance life science research.
Core Business Areas
- Cellular and Molecular Products: Includes products for cell culture, electroporation, and gene delivery, used in drug discovery and development.
- Physiology Products: Encompasses instruments for measuring and recording physiological parameters in animals and humans, used in preclinical research and drug development.
- Data Acquisition and Analysis: Provides software and hardware for data acquisition, analysis, and visualization, used across various life science applications.
Leadership and Structure
Harvard Bioscience is led by a CEO and senior management team. The organizational structure includes departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Harvard Apparatus Ventilators: Small animal ventilators used in preclinical research. Market share data not readily available. Competitors include Ugo Basile and Kent Scientific.
- Coulbourn Instruments: Behavioral pharmacology research systems. Market share data not readily available. Competitors include Med Associates and Lafayette Instrument.
- DSI Implants: Implantable telemetry solutions for physiological monitoring. Market share data not readily available. Competitors include Data Sciences International (DSI, now part of Integra LifeSciences).
Market Dynamics
Industry Overview
The life science research market is driven by increasing R&D spending, advancements in biotechnology, and the growing demand for personalized medicine.
Positioning
Harvard Bioscience is positioned as a provider of specialized tools and technologies for life science research, focusing on niche applications and customized solutions.
Total Addressable Market (TAM)
The global life science tools market is expected to reach hundreds of billions of dollars. Harvard Bioscience targets specific segments within this market, focusing on preclinical research and drug discovery.
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Diverse product portfolio
- Strong focus on specialized applications
- Global distribution network
Weaknesses
- Relatively small size compared to larger competitors
- Dependence on research funding
- Limited pricing power
- Past instances of financial instability
Opportunities
- Expansion into emerging markets
- Development of new products and technologies
- Strategic acquisitions of complementary businesses
- Partnerships with research institutions
Threats
- Competition from larger, more established companies
- Fluctuations in research funding
- Technological obsolescence
- Economic downturns
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- DHCN
Competitive Landscape
Harvard Bioscience faces competition from larger players with greater resources. Its advantage lies in its specialized product offerings and established brand reputation.
Major Acquisitions
Data Sciences International (DSI)
- Year: 2018
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expanded Harvard Bioscience's offering in implantable telemetry and physiological monitoring.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, with fluctuations based on research funding and economic conditions.
Future Projections: Analyst estimates vary, but projections suggest moderate growth driven by new product development and market expansion.
Recent Initiatives: Recent initiatives may include acquisitions, new product launches, and strategic partnerships.
Summary
Harvard Bioscience is a niche player in the life science research market with a long history and specialized product portfolio. Its strengths lie in its brand reputation and focus on specific applications. However, it faces challenges from larger competitors and fluctuations in research funding. Future growth depends on innovation, market expansion, and strategic acquisitions.
Similar Companies
ILMN
Illumina Inc
ILMN
Illumina Inc
MNTX
Manitex International Inc
MNTX
Manitex International Inc
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harvard Bioscience Inc
Exchange NASDAQ | Headquaters Holliston, MA, United States | ||
IPO Launch date 2000-12-07 | President, CEO & Chairman Mr. James W. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 330 | |
Full time employees 330 | |||
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.